Financing Cash Flow
Alnylam Pharmaceuticals Financing Cash Flow increased by 103.5% to $15.71M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.9%, from $46.08M to $15.71M. Over 3 years (FY 2021 to FY 2024), Financing Cash Flow shows a downward trend with a -38.2% CAGR.
Analysis
How to read this metric
A large negative value typically indicates a company is returning capital to shareholders or paying down debt, while a positive value suggests the company is raising external capital to fund operations or acquisitions.
Detailed definition
This metric represents the net flow of cash between a company and its capital providers, including shareholders and lend...
Peer comparison
Large-cap peers like Microsoft or Alphabet similarly show large negative financing outflows due to aggressive share repurchase programs and dividend distributions.
net_cash_from_financingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $329.81M | $573.84M | $292.29M | $34.96M | $30.34M | $297.02M | $63.44M | $46.37M | $53.39M | $33.14M | $39.23M | $28.91M | $131.50M | $102.76M | $31.00M | $46.08M | $51.76M | -$448.35M | $15.71M |
| QoQ Change | — | +74.0% | -49.1% | -88.0% | -13.2% | +879.1% | -78.6% | -26.9% | +15.1% | -37.9% | +18.4% | -26.3% | +354.8% | -21.9% | -69.8% | +48.7% | +12.3% | -966.2% | +103.5% |
| YoY Change | — | — | — | — | -90.8% | -48.2% | -78.3% | +32.7% | +76.0% | -88.8% | -38.2% | -37.7% | +146.3% | +210.1% | -21.0% | +59.4% | -60.6% | -536.3% | -65.9% |
Financing Cash Flow at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's financing cash flow?
- Alnylam Pharmaceuticals (ALNY) reported financing cash flow of $15.71M in Q1 2026.
- How has Alnylam Pharmaceuticals's financing cash flow changed year-over-year?
- Alnylam Pharmaceuticals's financing cash flow decreased by 65.9% year-over-year, from $46.08M to $15.71M.
- What is the long-term trend for Alnylam Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's financing cash flow has grown at a -38.2% compound annual growth rate (CAGR), from $1.25B to $294.16M.
- What does financing cash flow mean?
- The total amount of money a company spends or receives from borrowing debt and managing its own shares and dividends.